Abstract
Denosumab, a human monoclonal antibody directed against the receptor activator of nuclear factor-κB ligand （RANKL）, is used for the treatment of patients with metastatic cancer of the bone or osteoporosis. Recent reports have demonstrated that denosumab can induce osteonecrosis of the jaw, but its epidemiology and pathogenesis have not been fully clarified. This report presents the case of a 70-year-old female with breast cancer exhibiting bone metastases who developed osteonecrosis of the jaw （ONJ） while receiving denosumab. We performed surgical treatment and achieved successful healing.
